Literature DB >> 7788131

Comparison of carbamazepine and lithium in the prophylaxis of bipolar disorders. A meta-analysis.

R Dardennes1, C Even, F Bange, A Heim.   

Abstract

BACKGROUND: This meta-analysis assessed the equipotency of carbamazepine and lithium prophylaxis in bipolar disorder.
METHOD: We selected only randomised, double-blind, controlled studies comparing carbamazepine with lithium from a manual and computerised search, and subjected them to a quality inventory. Their statistical results were weighted by their quality score and combined.
RESULTS: Four studies met our criteria, yielding, overall, P = 0.15. This result is not straightforward because the studies showed significant heterogeneity (P < 0.01).
CONCLUSION: Differences in statistical power and sensitivity of outcome measure explain this heterogeneity and the conflicting results of the studies. Therefore, the prophylactic efficacy of carbamazepine remains questionable.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7788131     DOI: 10.1192/bjp.166.3.378

Source DB:  PubMed          Journal:  Br J Psychiatry        ISSN: 0007-1250            Impact factor:   9.319


  12 in total

Review 1.  Polytherapy in bipolar disorder.

Authors:  Daniel Lin; Hiram Mok; Lakshmi N Yatham
Journal:  CNS Drugs       Date:  2006       Impact factor: 5.749

Review 2.  The International College of Neuro-Psychopharmacology (CINP) Treatment Guidelines for Bipolar Disorder in Adults (CINP-BD-2017), Part 2: Review, Grading of the Evidence, and a Precise Algorithm.

Authors:  Konstantinos N Fountoulakis; Lakshmi Yatham; Heinz Grunze; Eduard Vieta; Allan Young; Pierre Blier; Siegfried Kasper; Hans Jurgen Moeller
Journal:  Int J Neuropsychopharmacol       Date:  2017-02-01       Impact factor: 5.176

Review 3.  Efficacy of pharmacotherapy in bipolar disorder: a report by the WPA section on pharmacopsychiatry.

Authors:  Konstantinos N Fountoulakis; Siegfried Kasper; Ole Andreassen; Pierre Blier; Ahmed Okasha; Emanuel Severus; Marcio Versiani; Rajiv Tandon; Hans-Jürgen Möller; Eduard Vieta
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2012-06       Impact factor: 5.270

Review 4.  Long term treatment of bipolar disorder.

Authors:  T Silverstone; S Romans
Journal:  Drugs       Date:  1996-03       Impact factor: 9.546

Review 5.  Suicidal behaviour in bipolar disorder: risk and prevention.

Authors:  Leonardo Tondo; Göran Isacsson; Ross Baldessarini
Journal:  CNS Drugs       Date:  2003       Impact factor: 5.749

Review 6.  Atypical antipsychotics for the treatment of bipolar disorder: more shadows than lights.

Authors:  Salvatore Gentile
Journal:  CNS Drugs       Date:  2007       Impact factor: 5.749

Review 7.  Carbamazepine for schizophrenia.

Authors:  Stefan Leucht; Bartosz Helfer; Markus Dold; Werner Kissling; John McGrath
Journal:  Cochrane Database Syst Rev       Date:  2014-05-02

Review 8.  Efficacy of Carbamazepine and Its Derivatives in the Treatment of Bipolar Disorder.

Authors:  Anna Grunze; Benedikt L Amann; Heinz Grunze
Journal:  Medicina (Kaunas)       Date:  2021-04-30       Impact factor: 2.430

9.  Carbamazepine treatment of bipolar disorder: a retrospective evaluation of naturalistic long-term outcomes.

Authors:  Chia-Hui Chen; Shih-Ku Lin
Journal:  BMC Psychiatry       Date:  2012-05-23       Impact factor: 3.630

Review 10.  Acute and long-term treatment of mania.

Authors:  Eduard Vieta; Jose Sanchez-Moreno
Journal:  Dialogues Clin Neurosci       Date:  2008       Impact factor: 5.986

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.